ReviewBlood advances2026
Venous thromboembolism is not associated with plasmin(ogen): reevaluating plasmin and mechanisms that degrade fibrin.
Review in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
abstractThe plasminogen activation and plasmin activity (PA) system is a central mechanism for degrading fibrin and has long been viewed as essential for preventing venous thrombosis/thromboembolism. However, clinical and experimental data challenge this paradigm. Here, we examine evidence that reduced PA does not predispose individuals to venous thrombosis/thromboembolism. We discuss potential mechanisms that may rationalize this apparent paradox, including compensatory vascular and inflammatory pathways that may degrade intravascular fibrin. These data suggest venous thromboembolism is a multifactorial disease in which an impaired PA system is neither necessary nor sufficient to drive thrombosis. We also discuss alternative biological roles of the PA system. Reframing the role of the PA system has important implications for developing therapies that modulate fibrinolysis. A more nuanced understanding of PA biology may enable strategies that balance bleeding risk with efficient clot resolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.